News
1Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea.
Tbe FDA approved retifanlimab-dlwr (Zynyz; Incyte), a PD-1-targeting mAb, in combination with chemotherapy for patients with inoperable or metastatic squamous cell carcinoma of the anal canal (SCAC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback